MX2023008738A - Cápsides de virus adenoasociados y canales iónicos controlados por ligandos diseñados para el tratamiento contra epilepsia focal y dolor neuropático. - Google Patents

Cápsides de virus adenoasociados y canales iónicos controlados por ligandos diseñados para el tratamiento contra epilepsia focal y dolor neuropático.

Info

Publication number
MX2023008738A
MX2023008738A MX2023008738A MX2023008738A MX2023008738A MX 2023008738 A MX2023008738 A MX 2023008738A MX 2023008738 A MX2023008738 A MX 2023008738A MX 2023008738 A MX2023008738 A MX 2023008738A MX 2023008738 A MX2023008738 A MX 2023008738A
Authority
MX
Mexico
Prior art keywords
neuropathic pain
focal epilepsy
adeno
associated virus
ion channels
Prior art date
Application number
MX2023008738A
Other languages
English (en)
Spanish (es)
Inventor
Annahita Keravala
Edward Yeh
Albena Kantardzhieva
Original Assignee
Trames Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trames Bio Inc filed Critical Trames Bio Inc
Publication of MX2023008738A publication Critical patent/MX2023008738A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023008738A 2021-01-25 2022-01-25 Cápsides de virus adenoasociados y canales iónicos controlados por ligandos diseñados para el tratamiento contra epilepsia focal y dolor neuropático. MX2023008738A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163141124P 2021-01-25 2021-01-25
US202163141121P 2021-01-25 2021-01-25
US202163285929P 2021-12-03 2021-12-03
PCT/US2022/013658 WO2022159871A1 (en) 2021-01-25 2022-01-25 Adeno-associated virus capsids and engineered ligand-gated ion channels for treating focal epilepsy and neuropathic pain

Publications (1)

Publication Number Publication Date
MX2023008738A true MX2023008738A (es) 2023-09-12

Family

ID=82549286

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008738A MX2023008738A (es) 2021-01-25 2022-01-25 Cápsides de virus adenoasociados y canales iónicos controlados por ligandos diseñados para el tratamiento contra epilepsia focal y dolor neuropático.

Country Status (9)

Country Link
US (1) US20240108760A1 (cg-RX-API-DMAC7.html)
EP (1) EP4281551A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024505197A (cg-RX-API-DMAC7.html)
KR (1) KR20230149299A (cg-RX-API-DMAC7.html)
AU (1) AU2022211055A1 (cg-RX-API-DMAC7.html)
CA (1) CA3205877A1 (cg-RX-API-DMAC7.html)
IL (1) IL304511A (cg-RX-API-DMAC7.html)
MX (1) MX2023008738A (cg-RX-API-DMAC7.html)
WO (1) WO2022159871A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025188847A1 (en) * 2024-03-07 2025-09-12 The Texas A&M University System Method for treating epilepsy
WO2025230969A1 (en) * 2024-05-02 2025-11-06 4D Molecular Therapeutics Inc. Aav variants with improved cns tropism and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1668143B1 (en) * 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
WO2015126972A1 (en) * 2014-02-21 2015-08-27 University Of Florida Research Foundation, Inc. Methods and compositions for gene delivery to on bipolar cells
AU2016324317A1 (en) * 2015-09-17 2018-03-08 Coda Biotherapeutics, Inc. Compositions and methods for treating neurological disorders
EP3468545B1 (en) * 2016-06-08 2026-08-05 President and Fellows of Harvard College Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, rett syndrome, and fragile x syndrome
IL274702B2 (en) * 2017-11-27 2026-04-01 Coda Biotherapeutics Inc Compounds and methods for neurological diseases
WO2019246480A1 (en) * 2018-06-21 2019-12-26 The Board Of Regents Of The University Of Texas System Correction of dystrophin exon 43, exon 45, or exon 52 deletions in duchenne muscular dystrophy

Also Published As

Publication number Publication date
AU2022211055A9 (en) 2024-07-11
KR20230149299A (ko) 2023-10-26
EP4281551A1 (en) 2023-11-29
US20240108760A1 (en) 2024-04-04
EP4281551A4 (en) 2025-06-04
IL304511A (en) 2023-09-01
JP2024505197A (ja) 2024-02-05
CA3205877A1 (en) 2022-07-28
AU2022211055A1 (en) 2023-08-17
WO2022159871A1 (en) 2022-07-28

Similar Documents

Publication Publication Date Title
JP2020508648A5 (cg-RX-API-DMAC7.html)
PH12020551938A1 (en) Liver targeting adeno-associated viral vectors
ZA202202242B (en) Isolated modified vp1 capsid protein of aav5
MX2018014152A (es) Composiciones y métodos para tratar la enfermedad de huntington.
WO2018022608A3 (en) Novel adeno-associated virus capsid proteins
WO2018204803A8 (en) Compositions and methods of treating huntington's disease
EP2561073A4 (en) VECTORS TO OBTAIN THE CENTRAL NERVOUS SYSTEM AND METHOD FOR THEIR USE
MX2021014700A (es) Variantes de vector del virus asociado a adeno para edicion genomica de alta eficacia y sus metodos.
WO2017066764A3 (en) Modification of n-terminal region of capsid proteins for enhanced properties of adeno-associated viruses
WO2012145509A3 (en) Adeno-associated-virus rep sequences, vectors, and viruses
MX2018007234A (es) Vectores virales adenoasociados utiles en el tratamiento de atrofia muscular espinal.
RU2016123086A (ru) Способы и композиции для лечения болезни хантингтона
NZ701693A (en) Composition and methods for highly efficient gene transfer using aav capsid variants
WO2013173512A3 (en) High-transduction-efficiency raav vectors, compositions, and methods of use
SG10201809075XA (en) Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
PH12020551319A1 (en) Viral vectors comprising rdh12 coding regions and methods of treating retinal dystrophies
AU2020299026A8 (en) Methods and AAV vectors for in vivo transduction
WO2019222314A8 (en) Raav vectors encoding of lysosomal beta-galactosidase (glb1) and cathepsin a
PH12021552577A1 (en) Engineered producer cell lines and methods of making and using the same
WO2014036468A3 (en) Aav mediated aquaporin gene transer to treat sjogren's syndrome
WO2022229702A3 (en) Aav8 capsid variants with enhanced liver targeting
EP4330413A4 (en) Adeno-associated viral vectors for cochlear transduction
MX2020002148A (es) Vectores adenoasociados recombinantes.
IL304511A (en) Adeno-associated capsid virus and transgenic ion channels for the treatment of focal epilepsy and neuropathic pain
WO2024145474A3 (en) Compositions and methods for regulating mapt